Tirzepatide is a GLP-1 receptor agonist peptide widely used in metabolic and weight management research. It features high purity (≥99%), excellent stability, and consistent quality. Supplied as lyophilized powder, it is easy to store and transport. Suitable for research applications with customizable specifications and reliable supply.Tirzepatide: A Detailed Introduction (≈500 words)
Tirzepatide, sold under brand names Mounjaro (for diabetes) and Zepbound (for weight loss), is a groundbreaking, first-in-class dual GLP-1/GIP receptor agonist developed by Eli Lilly and Company. Approved by the U.S. FDA in 2022 for type 2 diabetes and in 2023 for chronic weight management, it represents a major advance in treating metabolic disorders.
As a synthetic peptide, tirzepatide’s unique mechanism lies in its ability to mimic and activate two key incretin hormones: Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) . This dual action delivers powerful, synergistic effects. It stimulates glucose-dependent insulin secretion, suppresses elevated glucagon release, and significantly delays gastric emptying, which promotes a prolonged feeling of fullness and reduces overall calorie intake . The GIP component further enhances insulin sensitivity and helps regulate fat metabolism, leading to greater improvements in body weight and metabolic profile compared to single-target GLP-1 agonists.
Administered as a once-weekly subcutaneous the treatment follows a gradual dose-titration schedule . The starting dose is 2.5 mg, increased after 4 weeks to 5 mg, with further increments to 10 mg or 15 mg based on therapeutic response and tolerance . This slow escalation helps minimize side effects, which are primarily gastrointestinal: nausea, diarrhea, vomiting, and constipation. These effects are usually mild-to-moderate, occur most frequently during the initial dose-adjustment phase, and tend to diminish over time.
Clinically, tirzepatide has demonstrated exceptional efficacy. For type 2 diabetes, it can lower HbA1c by up to 2.5%, often outperforming older antidiabetic drugs. For weight management, patients typically lose 15–25 kg (15–25% of body weight) over a year, making it one of the most effective pharmaceutical weight-loss treatments available . It also improves cardiovascular risk factors by reducing blood pressure and harmful triglyceride levels.
However, it carries important contraindications. It is not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome type 2 (MEN 2). It is not intended for type 1 diabetes or diabetic ketoacidosis. While generally safe, patients must be monitored for rare but serious risks like pancreatitis, gallbladder disease, and severe allergic reactions.
In summary, tirzepatide is a revolutionary therapy that addresses both diabetes and obesity simultaneously. Its dual-action mechanism, weekly dosing convenience, and profound efficacy have established it as a leading option for managing the global epidemic of metabolic diseases.
Tirzepatide Key Information Table
Category Details
Drug Class First-in-class dual GLP-1/GIP receptor agonist
Brand Names Mounjaro (type 2 diabetes); Zepbound (chronic weight management)
Developer Eli Lilly and Company
Approval Indications 1. Type 2 diabetes mellitus in adults (202 2. Chronic weight management in adults with obesity or overweight (2023 FDA approval)
Mechanism of Action Activates both GLP-1 and GIP receptors; promotes glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, enhances satiety, and improves fat & glucose metabolism
Administration Subcutaneous once weekly; gradual dose titration (starting at 2.5 mg, up to 15 mg maximum)
Common Adverse Reactions Mild-to-moderate gastrointestinal symptoms: nausea, diarrhea, vomiting, constipation (mostly transient during dose escalation)
Severe Warnings & Contraindications 1. Contraindicated in patients with personal/family history of medullary thyroid carcinoma ( 2. Contraindicated in patients with Multiple Endocrine Neoplasia Syndrome type 2 (M 3. Not for type 1 diabetes or diabetic ketoacid 4. Risk of pancreatitis, gallbladder disease, severe allergic reactions (rare)
CoreTirzepatide Usage Instructions
Tirzepatide is a long-acting injectable prescription medication for adults with type 2 diabetes and chronic obesity. This guide outlines critical usage rules to ensure safety and therapeutic efficacy, and patients must follow healthcare providers’ specific instructions alongside this general guidance.
Administration Method
Tirzepatide is administered subcutaneously once weekly, at any time of day, with or without meals. Recommended sites include the abdomen, thigh, or upper arm; rotate is sites weekly to avoid local skin irritation, and never inject into bruised, red, or damaged skin. Each weekly dose should be taken on the same day every week, and if a dose is missed, take it as soon as remembered within 4 days. If more than 4 days pass, skip the missed dose and resume the regular schedule, never double the dose to compensate.
Dosage Titration
Dose adjustment follows a gradual plan to reduce gastrointestinal side effects. The initial starting dose is 2.5 mg weekly for 4 weeks, which is a treatment initiation phase, not a therapeutic dose. After 4 weeks, increase the dose to 5 mg weekly. Based on blood glucose control, weight loss effect and tolerance, the dose can be further increased to 10 mg, then 15 mg weekly at 4-week intervals. The maximum recommended weekly dose is 15 mg, and do not exceed this limit without explicit medical approval.
Precautions
Before use, inspect the solution: it should be clear and colorless, and discard it if cloudy or contains particles. Patients with a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe allergy to tirzepatide must not use this drug. During treatment, common mild side effects include nausea, diarrhea, and constipation, which usually subside over time. Seek immediate medical help if severe allergic reactions, pancreatitis, gallbladder problems, or suicidal thoughts occur.
This drug is not suitable for type 1 diabetes or diabetic ketoacidosis. Patients with kidney or liver impairment need no routine dose adjustment, but should consult a doctor for monitoring. Store unused tirzepatide in the refrigerator, and avoid freezing or direct sunlight exposure. Adhere to regular blood glucose and weight checks during treatment to help doctors adjust the treatment plan timely.
United States
Germany
Kenya
